You are here

Phase III Trial of Ocinaplon Placed on Hold by FDA

HACKENSACK, N.J., Oct. 2 /PRNewswire-FirstCall/ -- DOV Pharmaceutical, Inc. announced that today the Food and Drug Administration placed the start of the Phase III pivotal trial of ocinaplon, DOV's novel anti-anxiety product candidate, on hold. The FDA has requested that DOV produce additional safety information satisfactory to the agency in order to remove the hold and permit DOV to commence the trial. The company intends to diligently assemble the necessary information in accordance with FDA comments and communicate further with the FDA as soon as reasonably practicable.

Source: DOV Pharmaceutical, Inc.

Recent Headlines

One in Five Kids’ Office Visits Results in an Off-Label Rx
Related Settlement Would End Many but Not All Lawsuits
Chronic Kidney Patients With Hyperphosphatemia May Be Another Market for the Drug
Nitrosamine Impurity Also Affects Other Ranitidine Drugs
Mesh Implants, Now Banned by FDA, Work as Well as Hysterectomy
Judicious Use of Antibiotics May Not Be Enough To Defeat Bacteria That Carry On By Going Into a Dormant State
KRAS Oncogene Is a Problematic Target So Researchers Are Trying Workdarounds
Understanding Neural Ensembles in Infralimbic Cortex May Lead To Improved Addiction Treatment
Disrupting Gut Microbiome Could Be Key